Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics Inc (RLMD)
:RLMD
RLMD Stock Chart & Stats
$2.26
-$0.01(-3.06%)
At close: 4:00 PM EST
$2.26
-$0.01(-3.06%)
Day’s Range― - ―
52-Week Range$0.24 - $5.12
Previous CloseN/A
Volume447.03K
Average Volume (3M)1.50M
Market Cap
$307.27M
Enterprise Value$52.83M
Total Cash (Recent Filing)$13.89M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Mar 24, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding73,333,626
10 Day Avg. Volume1,227,198
30 Day Avg. Volume1,500,462
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.37
Forecast
1Y Price Target
$10.00Price Target Upside342.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessNDV-01 for high-grade non-muscle invasive bladder cancer showed an overall response rate of 85% and high-grade recurrence-free survival in patients with papillary disease of 83%.
Competitive AdvantageNDV-01's novel sustained-release formulation could have blockbuster potential due to its ease of administration and increased efficacy.
Market OpportunityThe in-licensing of NDV-01 for treating NMIBC represents a multi-billion opportunity for Relmada Therapeutics Inc.
Bears Say
Development Re-evaluationThe company is re-evaluating further development of ‘P11 (novel psilocybin) as part of its prioritization efforts.
Uncertain Financial OutlookThe company ended the year with $27M in cash, and additional data and updates from the pipeline are awaited before making any substantive comments regarding the pipeline assets.
Valuation ConcernsAt this point, the product is not being added into the valuation, and the recommendation remains Market Perform.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was $0.24 and its highest was $5.12 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is $307.27M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Mar 24, 2026 which is in 114 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.424 by $0.124.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.17.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 73,333,626 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.424. Following the earnings report the stock price went up 1.804%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in RLMD
Relmada Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (342.48% Upside)
$10.00 (342.48% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 740.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $178.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 50.3%
Last 30 Days ▲ 50.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.04%
12-Months-Change
Fundamentals
Return on Equity
-196.79%
Trailing 12-Months
Asset Growth
-73.30%
Trailing 12-Months
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of central nervous system (CNS) diseases. The company is primarily engaged in the research and development of novel compounds and formulations aimed at addressing unmet medical needs within the CNS sector. Relmada's lead product candidate is REL-1017 (esmethadone), an NMDA receptor antagonist, which is being investigated for the treatment of major depressive disorder (MDD).
RLMD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was overwhelmingly positive, highlighting significant achievements in clinical trials, regulatory alignment, and financial stability. The only notable concern was the reduction in cash reserves prior to the recent capital raise, which has since been addressed.View all RLMD earnings summariesRLMD Stock 12 Month Forecast
Average Price Target
$10.00
▲(342.48% Upside)
Technical Analysis
XBiotech
―
Repare Therapeutics
―
Prelude Therapeutics
―
Spruce Biosciences
―
Werewolf Therapeutics
―
Ownership Overview
8.94% Insiders
2.01% Mutual Funds
10.79% Other Institutional Investors
75.27% Public Companies and
Individual Investors